18F-FDG PET/CT of patients with cancer: Comparison of whole-body and limited whole-body technique

American Journal of Roentgenology

Volumn 195, Issue 6, 2010, Pages 1397-1403

  Osman, Medhat M ^a   Chaar, Bassem T ^a   Muzaffar, Razi ^a   Oliver, Dana ^b   Reimers, Hans Joachim ^b   Walz, Bruce ^a   Nguyen, Nghi C ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

18F FDG; Cancer imaging; PET CT; True whole body imaging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BRAIN; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FOLLOW UP; HUMAN; LIMB; MAJOR CLINICAL STUDY; PATHOLOGY; PRIORITY JOURNAL; SKULL; WHOLE BODY PET; AGED; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; NEOPLASM; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING; WHOLE BODY IMAGING;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 78649756042     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.09.3731     Document Type: Article

References (22)

1. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med 2002; 53:89-112 (Pubitemid 34177873)
2. Czernin J, Allen-Auerback M, Schelbert HR. Improvements in cancer staging with PET/CT: literature- based evidence as of September 2006. J Nucl Med 2007; 48[suppl 1]:78S-88S
3. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003; 44:1200-1209 (Pubitemid 39655178)
4. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18- 2-fluoro- 2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004; 22:4357-4368 (Pubitemid 41185156)
5. Mawlawi O, Townsend DW. Multimodality imaging: an update on PET/CT technology. Eur J Nucl Med Mol Imaging 2009; 36[suppl 1]:S15-S29
6. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003; 290:3199-3206 (Pubitemid 38020681)
7. Von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006; 238:405-422 (Pubitemid 43134354)
8. Nguyen NC, Chaar BT, Osman MM. Prevalence and patterns of soft tissue metastasis: detection with true whole-body F-18 FDG PET/CT. BMC Med Imaging 2007; 12;7-8
9. 18F]-fluoro-2- deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer? Chest 2004; 126:755-760
10. 18F-FDG PET/CT imaging for patients with malignant melanoma. Nucl Med Commun 2007; 28:688-695
11. Browne J, De Pierro A. A row-action alternative to the EM algorithm for maximizing likelihoods in emission tomography. IEEE Trans Med Imaging 1996; 15:687-699 (Pubitemid 126780358)
12. Townsend DW, Cherry SR. Combining anatomy and function: the path to true image fusion. Eur Radiol 2001; 11:1968-1974
13. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41:1369-1379 (Pubitemid 30643379)
14. Huston F, Jackson R, Osman MM. Whole-body F-18 FDG PET/CT: the need for standardized field of view. (abstract) J Nucl Med 2005; 46:523P
15. Coleman RE, Delbeke D, Guibeteau MJ, et al. Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the joint working group of American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Nucl Med 2005; 46:1225-1239 (Pubitemid 43741086)
16. Townsend DW, Carney PJ, Yap JT, Hall NC. PET/ CT today and tomorrow. J Nucl Med 2004; 45[suppl 1]:4S-14S
17. Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 2003; 226:181-187
18. National Comprehensive Cancer Network Website. Clinical practice guidelines in oncology: non-small cell lung cancer, version 1.2007. www.nccn.org. Accessed April 27, 2009
19. Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005; 46:752-757 (Pubitemid 43750749)
20. Agress H Jr, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004; 230:417-422
21. Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the National Oncologic PET registry. J Nucl Med 2008; 49:1928-1935
22. Coleman RE, Hillner BE, Shields AF, et al. PET and PET/CT reports: observations from the National Oncologic PET Registry. J Nucl Med 2010; 51:158-163